Trial Profile

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belinostat (Primary) ; Guadecitabine (Primary)
Indications Chondrosarcoma
Focus Therapeutic Use

Most Recent Events

18 Dec 2024 Planned End Date changed from 1 Jan 2025 to 1 Jun 2025.
18 Dec 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jun 2025.
04 Jun 2024 Results (n=19) assessing correlative analysis of NCI 10330 were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com